Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00031798 · ClinicalTrials.gov registry record · Phase 3
Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors
A Phase 3 study, sponsored by Wake Forest University Health Sciences.
- Terminated
- Registry status
- Phase 3
- Development phase
NCT00031798 is a Phase 3 study that was terminated before completion, run by Wake Forest University Health Sciences.
The verdict
NCT00031798, a Phase 3 study, was terminated before completion, sponsored by Wake Forest University Health Sciences.
- TERMINATED
- Registry status
- Phase 3
- Development phase
Study Summary
RATIONALE: Methylphenidate may decrease side effects of radiation therapy. It is not yet known if methylphenidate is effective in improving quality of life in patients with primary or metastatic brain tumors. PURPOSE: Randomized phase III trial to determine the effectiveness of methylphenidate in improving quality of life in patients who have brain tumors and are undergoing radiation therapy.
Interventions
- PROCEDURE quality-of-life assessment
- RADIATION radiation therapy
- DRUG methylphenidate hydrochloride
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-04-01 |
| Est. Completion | 2006-05-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00031798
The ClinicalTrials.gov registry entry for NCT00031798 describes a study currently listed as terminated, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which quality-of-life assessment is the first listed.
NCT00031798 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00031798 about?
NCT00031798 is a clinical study titled "Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors". RATIONALE: Methylphenidate may decrease side effects of radiation therapy. It is not yet known if methylphenidate is effective in improving quality of life in patients with primary or metastatic brain tumors. PURPOSE: Randomized phase III trial to determine the effectiveness of methylphenidate in i...
What is the current status of trial NCT00031798?
This trial is currently terminated. It is a Phase 3 study. The study started on 2002-04-01. Estimated completion is 2006-05-01.
What interventions are being tested in trial NCT00031798?
The interventions under investigation include: quality-of-life assessment (PROCEDURE), radiation therapy (RADIATION), methylphenidate hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00031798?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.